title: Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
abstract: Imatinib (glivec), formerly known as STI571) effectively blocks the ATP-binding site of the bcr/abl fusion protein thereby inactivating selectively the tyrosine kinase activity of bcr/abl. Therefore, it is a promising drug in Philadelphia chromosome positive chronic myeloid leukemia showing high hematologic and cytogenetic response rates combined with a mild toxicity profile. Here we report two cases of squamous cell carcinoma of the skin, which appeared in the photo-exposed areas in two elderly patients treated for advanced chronic myeloid leukemia with imatinib. The role of chemotherapy, chronic sun exposure and of possible additional risk factors such as human papillomavirus infection is discussed.
authors.affiliation: Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Virchow, Charité, Humboldt Universität Berlin, Germany. gökben.baskaynak@charite.de
authors.forename: Gökben
authors.initials: G
authors.lastname: Baskaynak
authors.forename: Karl-Anton
authors.initials: KA
authors.lastname: Kreuzer
authors.forename: Michaela
authors.initials: M
authors.lastname: Schwarz
authors.forename: Johannes
authors.initials: J
authors.lastname: Zuber
authors.forename: Heike
authors.initials: H
authors.lastname: Audring
authors.forename: Hanno
authors.initials: H
authors.lastname: Riess
authors.forename: Bernd
authors.initials: B
authors.lastname: Dörken
authors.forename: Philipp
authors.initials: P
authors.lastname: le Coutre
mesh_terms: D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D002294:Carcinoma, Squamous Cell / Q000209:etiology*; D003043:Cocarcinogenesis; D003327:Coronary Disease / Q000150:complications; D003875:Drug Eruptions / Q000150:complications* / Q000209:etiology; D004417:Dyspnea / Q000139:chemically induced; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D005153:Facial Neoplasms / Q000209:etiology*; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009381:Neoplasms, Radiation-Induced / Q000209:etiology*; D016609:Neoplasms, Second Primary / Q000209:etiology*; D010198:Pancytopenia / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D010996:Pleural Effusion / Q000209:etiology; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D013472:Sunlight / Q000009:adverse effects; D014466:Ultraviolet Rays / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D006918:Hydroxyurea